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Diabetes is a progressive metabolic dis-
order that can ultimately lead to serious
chronic vascular complications including
renal failure, vision loss, and cardiac dys-
function (Ruiz and Chakrabarti, 2013).
Diabetic cardiomyopathy is responsible
for higher incidence of sudden cardiac
death and represents the leading cause of
morbidity and mortality among the dia-
betic patients (Aksnes et al., 2007; Chavali
et al., 2013). Previous studies have indi-
cated that oxidative stress and mitochon-
drial dysfunction were critically involved
in the etiology of diabetes-induced car-
diac dysfunction (Sugamura and Keaney,
2011; Styskal et al., 2012), that could
subsequently induce a cascade of com-
plex pathophysiological events character-
ized by early impairments of diastolic
function, development of cardiomyocyte
hypertrophy, myocardial fibrosis and car-
diomyocyte apoptosis, eventually leading
to heart failure (Huynh et al., 2014).
However, the underlying mechanisms of
diabetic cardiomyopathy are far from
understood and current therapeutic strate-
gies do not specifically aim at diabetic car-
diomyopathy and diabetes-induced heart
failure.
MicroRNAs (miRNAs, miRs), a novel
class of non-coding RNAs of 22∼24
nucleotides in length, act as post-
transcriptional regulators of gene expres-
sion by binding to the 3′-untranslated
region (3′-UTR) of target mRNA that
induces mRNA degradation and/or trans-
lational repression (Lim et al., 2005;
Van Rooij, 2011). Given that miRNAs
are crucially involved in many criti-
cal biological processes including cell
proliferation, apoptosis, necrosis, migra-
tion and differentiation (Bartel, 2004),
desregulated miRNAs contribute to many
human diseases including diabetes (Tyagi
et al., 2011; Shantikumar et al., 2012;
McClelland and Kantharidis, 2014) and
cardiovascular diseases (Xiao et al., 2012;
Fu et al., 2013; Vickers et al., 2014).
Recent studies demonstrate that aberrant
expression of miRNAs also participates
in the pathogenetic processes mediating
diabetic cardiomyopathy, where miR-1,
-133, -141, -206, -223 have been reported
upregulated, whereas miR-133a, -373,
and -499 downregulated (Shen et al.,
2011; Shantikumar et al., 2012; Asrih
and Steffens, 2013). Thus, it is of crucial
importance to gain insight into the role of
miRNAs in the development of diabetic
cardiomyopathy which will help clarify the
molecular mechanisms as well as identify
novel therapeutic strategies for diabetic
cardiomyopathy.
Cardiomyocyte hypertrophy, myocar-
dial fibrosis, and cardiomyocyte apoptosis
are important features of diabetic car-
diomyopathy (Ruiz and Chakrabarti,
2013). Downregulation of miR-133a
induces cardiomyocyte hypertrophy via
upregulating the expression of MEF2A
and MEF2C, two transcription factors
involved in myocardial hypertrophy (Feng
et al., 2010). While upregulation of miR-1
and -206 contributes to increased car-
diomyocyte apoptosis, via repressing the
expression of heat shock protein (Hsp)
60, PIM 1, and IGF-1 receptor (Yu et al.,
2008; Shan et al., 2010; Katare et al., 2011).
In addition, miR-373 is downregulated
in diabetic heart, which is supposed to
induce cardiac fibrosis via regulating the
expression of p300 (Feng et al., 2008; Chen
et al., 2010; Shen et al., 2011; Chavali
et al., 2014). Thus, these reports indicate
the critical contribution of miRNAs in
cardiomyocyte hypertrophy, myocardial
fibrosis, and cardiomyocyte apopto-
sis during the development of diabetic
cardiomyopathy.
Hyperglycemia, oxidative stress and
mitochondrial damage are involved in
the etiology of diabetes-induced cardiac
dysfunction and diabetic cardiomyopa-
thy (Shantikumar et al., 2012; Asrih
and Steffens, 2013; McClelland and
Kantharidis, 2014). Previous study has
shown that miR-499 and -133a were
markedly downregulated in the diabetic
cardiomyocytes, while normalization of
oxidant/antioxidant level by the treatment
of N-acetylcysteine (NAC) restored the
impaired expression of these miRNAs,
indicating that hyperglycemia-induced
downregulation of miR-499 and -133a
was oxidative stress dependent (Yildirim
et al., 2013). Similarly, miR-373 was
downregulated by hyperglycemia-induced
oxidative stress in diabetic cardiomyopa-
thy via p38 MAPK pathway (Shen et al.,
2011). MiR-141, a critical regulator of the
inner mitochondrial phosphate carrier
(Slc25a3), has been shown upregulated
in diabetic heart, thus leading to the
impaired mitochondrial ATP production
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in the pathogenesis of diabetic cardiomy-
opathy (Baseler et al., 2012). In terms
of cardiomyocyte glucose metabolism,
miR-223 was shown to be upregulated
in the left ventricular biopsies of diabetic
patients, which induced Glut4 protein
level in cardiomyocytes and contributed
to cardiomyocyte glucose uptake in vitro,
indicating that overexpression of miR-
223 might be a compensatory response
to restore glucose metabolism in diabetic
heart (Lu et al., 2010).
Accumulating evidence has indicated
that circulating miRNAs can be used as
sensitive biomarkers for certain diseases
such as cardiovascular diseases and can-
cers (Fabbri, 2010; Tijsen et al., 2012;
Xu et al., 2012). Despite that diabetes is
among the major risk factors for cardio-
vascular complications, researches inves-
tigating circulating miRNAs in diabetic
patients are quite limited. Zampetaki et al.
reported deregulation of 12 plasma miR-
NAs (miR-24, -21, -20b, -15a, -126, -191,
-197, -223, -320, -486, -150, and -28-3p)
in diabetic subjects, among which miR-
126 emerged as a predictor of diabetes
mellitus (Zampetaki et al., 2010). A sepa-
rate study identified 7 upregulated serum
miRNAs (miR-9, -29a, -30d, -34, -124, -
146a, and -375) in newly diagnosed type
2 diabetic patients as compared to suscep-
tible controls (Kong et al., 2011). Another
study identified elevation of miR-144, 192,
and 29a in the whole blood of diabetic
patients (Karolina et al., 2011), whereas no
change was found in miR-126 level which
was inconsistent with the report published
by Zampetaki et al. (2010). This may be
explained by different biosamples detected
(plasma vs. whole blood) in these two
studies (Zampetaki et al., 2010; Karolina
et al., 2011). In addition, miR-503 was
found to be enriched in the plasma of dia-
betic patients with critical limb ischemia
(Caporali et al., 2011). However, to date,
no specific circulating miRNA has been
identified in diabetic cardiomyopathy. The
diagnostic and predicted value of circu-
lating miRNAs as biomarkers for diabetic
cardiomyopathy remains to be further
explored.
Taken together, desregulated miRNAs
are potentially involved in the etiology
and pathogenetic processes of diabetic car-
diomyopathy. An in-depth understanding
of their functional roles and molecular
mechanisms in the development of dia-
betic cardiomyopathy will provide bet-
ter prospects to identify sensitive clinical
biomarkers and novel therapeutic targets
for diabetic cardiomyopathy.
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